Drugs / BISMUTH OXIDE
last change Dec 2021 re-read 9 days ago

BISMUTH OXIDE

Developed for
Helicobacter pylori infectious disease
Investigated by
National Taiwan University Hospital

Trials 2

2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial · 1 missed
Phase 3 NCT03148366 Feb 2015 → Dec 2019 Helicobacter pylori infectious disease National Taiwan University Hospital Completed Missed primary
Phase 41 trial · 1 met primary
Phase 4 NCT03555526 Dec 2017 → Sep 2021 Helicobacter pylori infectious disease National Taiwan University Hospital Unknown Met primary
Comparator or background therapy2 trials
Phase 4 NCT03208426 Comparator Oct 2017 → Dec 2019 Helicobacter pylori infectious disease National Taiwan University Hospital Unknown No outcome recorded
Phase 4 NCT03156855 Comparator Sep 2015 → Dec 2018 Helicobacter pylori infectious disease National Taiwan University Hospital Unknown Met primary

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as BISMUTH OXIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL4297546 ↗
Known as Bismuth trioxide ChEMBL registry synonym — accepted as the source's own label CHEMBL4297546 ↗
Known as Bismuth yellow ChEMBL registry synonym — accepted as the source's own label CHEMBL4297546 ↗
Known as Bismuthous oxide ChEMBL registry synonym — accepted as the source's own label CHEMBL4297546 ↗
Known as Bismuthum oxydatum ChEMBL registry synonym — accepted as the source's own label CHEMBL4297546 ↗
Known as dibismuth trioxide “D1-D10: (esomeprazole 40mg bid + dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days” NCT03156855 ↗
3

“D1-D10: (esomeprazole 40mg bid + Dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days” NCT03148366 ↗

NCT03555526 ↗

NCT03208426 ↗